Cardiovascular disease represents a major burden in people with type 2 diabetes, and the prevention of cardiovascular complications has become a main objective when treating at-risk people. Numerous cardiovascular outcome trials (CVOTs) were published in recent years that showed not only the cardiovascular safety, but also the efficacy, of new glucose-lowering therapies. However, almost all CVOTs used a placebo as comparator rather than an active agent, and there were no CVOTs that directly compared the cardiovascular effects between newer glucose-lowering agents—especially SGLT2 inhibitors versus GLP-1 receptor agonists.

Cardiovascular disease represents a major burden in people with type 2 diabetes, and the prevention of cardiovascular complications has become a main objective when treating at-risk people. Numerous cardiovascular outcome trials (CVOTs) were published in recent years that showed not only the cardiovascular safety, but also the efficacy, of new glucose-lowering therapies. However, almost all CVOTs used a placebo as comparator rather than an active agent, and there were no CVOTs that directly compared the cardiovascular effects between newer glucose-lowering agents—especially SGLT2 inhibitors versus GLP-1 receptor agonists.

Cardiovascular disease represents a major burden in people with type 2 diabetes, and the prevention of cardiovascular complications has become a main objective when treating at-risk people. Numerous cardiovascular outcome trials (CVOTs) were published in recent years that showed not only the cardiovascular safety, but also the efficacy, of new glucose-lowering therapies. However, almost all CVOTs used a placebo as comparator rather than an active agent, and there were no CVOTs that directly compared the cardiovascular effects between newer glucose-lowering agents—especially SGLT2 inhibitors versus GLP-1 receptor agonists.